Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Inhalt bereitgestellt von Proactive Investors. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Proactive Investors oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Player FM - Podcast-App
Gehen Sie mit der App Player FM offline!
Gehen Sie mit der App Player FM offline!
Race Oncology receives positive results from AML trial of Bisantrene
MP3•Episode-Home
Manage episode 431551800 series 2891889
Inhalt bereitgestellt von Proactive Investors. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Proactive Investors oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett sits down with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). The trial, which included patients with relapsed or refractory AML, demonstrated a 40% response rate, exceeding the efficacy threshold. The open-label trial combined intravenous RC110 bisantrene with chemotherapies clofarabine and fludarabine. Out of the treated patients, five experienced complete responses and one had a partial response, surpassing the goal of at least three complete responses. Tillett expressed gratitude to Professor Nagler and the Chaim Sheba Medical Centre team for their dedication over the past five years. The team’s efforts have contributed significantly to the historical evidence supporting bisantrene’s efficacy and have spurred further interest among clinicians. The company plans to initiate a new Phase 1/2 investigator-sponsored trial using RC220 bisantrene, a reformulated version, to meet the high unmet needs of AML patients. Race Oncology is focused on anthracycline combinations, aiming to provide cardio-protection and enhanced anticancer activity in solid tumours, as well as offering low-intensity treatment options for AML. #ProactiveInvestors #RaceOncology #ASX #AML, #CancerTreatment, #Bisantrene, #ClinicalTrials, #PharmaNews, #OncologyResearch, #ChemoTherapy, #CancerResearch, #HealthNews, #MedicalResearch, #Phase1Trial, #Phase2Trial, #AcuteMyeloidLeukemia, #CancerCare, #MedicalBreakthrough, #Oncology, #Hematology, #DrugDevelopment, #PatientCare #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 Episoden
MP3•Episode-Home
Manage episode 431551800 series 2891889
Inhalt bereitgestellt von Proactive Investors. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Proactive Investors oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett sits down with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). The trial, which included patients with relapsed or refractory AML, demonstrated a 40% response rate, exceeding the efficacy threshold. The open-label trial combined intravenous RC110 bisantrene with chemotherapies clofarabine and fludarabine. Out of the treated patients, five experienced complete responses and one had a partial response, surpassing the goal of at least three complete responses. Tillett expressed gratitude to Professor Nagler and the Chaim Sheba Medical Centre team for their dedication over the past five years. The team’s efforts have contributed significantly to the historical evidence supporting bisantrene’s efficacy and have spurred further interest among clinicians. The company plans to initiate a new Phase 1/2 investigator-sponsored trial using RC220 bisantrene, a reformulated version, to meet the high unmet needs of AML patients. Race Oncology is focused on anthracycline combinations, aiming to provide cardio-protection and enhanced anticancer activity in solid tumours, as well as offering low-intensity treatment options for AML. #ProactiveInvestors #RaceOncology #ASX #AML, #CancerTreatment, #Bisantrene, #ClinicalTrials, #PharmaNews, #OncologyResearch, #ChemoTherapy, #CancerResearch, #HealthNews, #MedicalResearch, #Phase1Trial, #Phase2Trial, #AcuteMyeloidLeukemia, #CancerCare, #MedicalBreakthrough, #Oncology, #Hematology, #DrugDevelopment, #PatientCare #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 Episoden
すべてのエピソード
×Willkommen auf Player FM!
Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.